{
  "pmcid": "12091215",
  "sha256": "de055556b19523173433bfe33f44967dd7fb2a363bd60edaa8599de692e4ee96",
  "timestamp_utc": "2025-11-09T23:26:22.489261+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.012545454545457,
    "reading_ease": 39.6188181818182,
    "word_count": 264
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of NPC-21 for CMV Prevention in Kidney Transplant Recipients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "multicenter, randomized, double-blind, placebo-controlled, phase 2 trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Adult KT recipients aged 18-75 years were enrolled from centers in the United States and Japan."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomized in a 4:1:4 ratio to receive monthly 6 mg/kg NPC-21, 12 mg/kg NPC-21, or placebo."
      },
      "Objective": {
        "score": 1,
        "evidence": "assessed the efficacy and safety of fiztasovimab (NPC-21), an anti-CMV monoclonal antibody, in kidney transplant (KT) recipients"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was CMV infection by week 16."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was stratified by region using an Interactive Response Technology system, with allocation concealed from investigators and patients."
      },
      "Blinding": {
        "score": 3,
        "evidence": "double-blind"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 87 participants were randomized: 38 to 6 mg/kg NPC-21, 11 to 12 mg/kg NPC-21, and 38 to placebo."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "CMV infections occurred in 76.3%, 81.8%, and 68.4% of patients in the 6 mg/kg NPC-21, 12 mg/kg NPC-21, and placebo groups, respectively"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "CMV disease occurred in 4.1% of the combined NPC-21 group versus 13.2% in the placebo group, with an absolute difference of −9.1 (95% CI −23.9 to 2.8)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were observed after NPC-21 administration."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 21,
    "max_score": 25
  }
}